Traditional Chinese medicinal composition for treating Alzheimer-type disease and preparation method thereof

Abstract

The invention provides a traditional Chinese medicinal composition for treating Alzheimer-type diseases, wherein the traditional Chinese medicinal composition comprises the following traditional Chinese medicinal raw materials forming active ingredients according to the weight: 7.5g of radix polygoni multiflori preparata, 5g of cultivated land, 7.5g of epimedium herb, 5g of cynomorium songaricum and 5g of dogwood. After 107 light-moderate AD patients are treated for 24 weeks and 48 weeks, the comparison result of MMSE (mini-mental state examination) curative effects are as follows: for the effective rate with 48-week treatment, the western-medicine control group is 55.77% and the Chinese-medicine group is 70.91%. According to the above results, for treating the Alzheimer-type diseases, the traditional Chinese medicinal composition for is better than the donepezil. When being applied clinically, the traditional Chinese medicinal composition is directly taken by is mixed with water, and is simple in use. The traditional Chinese medicine particles are packaged by an aluminium-foil bag without easy moisture absorption, the size is small and the carrying is convenient. The invention provides a new treatment direction for treating the Alzheimer-type diseases and has larger clinic application value.

Description

technical field [0001] The invention relates to traditional Chinese medicine, in particular to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating Alzheimer's dementia and a preparation method thereof. Background technique [0002] Alzheimer's Disease (AD) was first described by German scientist Alzheimer in 1907. It is a chronic brain degenerative disease with insidious onset. The clinical manifestations are progressive far and near memory impairment, decline in analysis and judgment, emotional changes, abnormal behavior, and even confusion. In the end, most of them die of pneumonia or urinary tract infection. The disease has become the fourth leading cause of death in western countries, second only to heart disease, tumor and stroke. The total prevalence in the United States is about 2.3 million. After the age of 60, the prevalence of AD doubles every five years. By the next 50 years, the population of AD pa...

AI Technical Summary

Problems solved by technology

Another drug, glutamate receptor blocker memantine, is expensive and has many side effects, which brings greater pressure on social security and personal economy

For the treatment of Alzheimer's disease (AD), these drugs are mainly aimed at improving symptoms, but cannot delay the development of the disease

Th...

Images